Department of Pathology and Hepatology, the 5th Medical Center, Chinese PLA General Hospital, China.
Peking University Hepatology Institute, Peking University People's Hospital, Peking University Health Science Center, Beijing, China.
EBioMedicine. 2019 Aug;46:227-235. doi: 10.1016/j.ebiom.2019.07.043. Epub 2019 Jul 23.
Whether achieving sustained virological response (SVR) in patients with hepatitis C attains complete elimination of hepatitis C virus (HCV) is unknown, because occult HCV infection (OCI), defined as the detection of HCV-RNA in hepatocytes or peripheral blood mononuclear cells (PBMC) in absence of serum HCV-RNA, may occur. We thus investigated the prevalence and clinical relevance of OCI.
Subjects from three hospitals who had achieved serum HCV clearance, including 60 of Direct-acting antiviral agents (DAAs) induced SVR, 50 of pegylated interferon plus ribavirin (PR) induced SVR, and 30 of spontaneous resolution, were subjected to detect HCV-RNA in liver by robust RNAscope assay and PBMC by qPCR. Paired liver biopsies at baseline and at SVR24 were analyzed.
OCI was detected in 16 of 140 subjects (11.4%), with 15.0% in DAA-based group, 10.0% in PR group and 6.7% in spontaneously resolved group. In DAA-based subgroups, the incidence of OCI was gradually increased in group of solely DAA(s) therapy, combining DAA and PR therapy and combining DAA and ribavirin therapy. OCI is more frequent in patients with genotype 3. No correlation between baseline viral load, interleukin-28B genotype, baseline transaminases, post-SVR transaminases and OCI were found. However, OCI was significantly linked with severity of fibrosis and active inflammation at post-SVR, even considering basal fibrosis status. In addition, both the magnitude and the frequency of fibrosis regression were lower in patients with OCI than in those without OCI. In the multivariate analysis, PR therapy was identified an independent negative prognostic factor for both hepatic inflammation (P = .022) and fibrosis regression (P = .015). Importantly, we found HCV relapse in one of the OCI patients at 48 weeks after the end of PR treatment.
HCV-RNA can persist in hepatocytes and/or PBMC in a certain of patients who achieved spontaneous or treatment-induced HCV RNA clearance from serum and associated with persistent histological abnormality. Our findings provide new insights into cure of HCV and could influence the following-up scenario after SVR.
慢性丙型肝炎患者达到持续病毒学应答(SVR)是否能实现丙型肝炎病毒(HCV)的完全清除尚不清楚,因为隐匿性 HCV 感染(OCI)定义为在无血清 HCV-RNA 的情况下在肝细胞或外周血单核细胞(PBMC)中检测到 HCV-RNA。因此,我们研究了 OCI 的流行率和临床相关性。
来自三家医院的受试者在血清 HCV 清除后,包括 60 例直接作用抗病毒药物(DAA)诱导的 SVR、50 例聚乙二醇干扰素加利巴韦林(PR)诱导的 SVR 和 30 例自发缓解的受试者,通过稳健的 RNAscope 检测肝组织中的 HCV-RNA,通过 qPCR 检测 PBMC 中的 HCV-RNA。对基线和 SVR24 时的配对肝活检进行分析。
在 140 名受试者中,有 16 名(11.4%)检测到 OCI,其中 DAA 组为 15.0%,PR 组为 10.0%,自发缓解组为 6.7%。在 DAA 组亚组中,单纯 DAA 治疗组、DAA 联合 PR 治疗组和 DAA 联合利巴韦林治疗组的 OCI 发生率逐渐增加。OCI 在基因型 3 患者中更为常见。未发现基线病毒载量、白细胞介素 28B 基因型、基线转氨酶、SVR 后转氨酶与 OCI 之间存在相关性。然而,OCI 与 SVR 后纤维化和炎症的严重程度显著相关,即使考虑到基础纤维化状态也是如此。此外,在 OCI 患者中,纤维化消退的幅度和频率均低于无 OCI 患者。在多变量分析中,PR 治疗被确定为肝炎症(P=0.022)和纤维化消退(P=0.015)的独立负预后因素。重要的是,我们在 PR 治疗结束后 48 周时发现一名 OCI 患者的 HCV 复发。
在某些从血清中自发或经治疗清除 HCV RNA 的患者中,HCV-RNA 可在肝细胞和/或 PBMC 中持续存在,并与持续的组织学异常相关。我们的发现为 HCV 的治愈提供了新的见解,并可能影响 SVR 后的随访情况。